Eisai Inc.

This study tests whether adding an experimental drug called E2814 to the approved Alzheimer's drug lecanemab can reduce harmful tau protein in the brain. It involves 105 people with early-stage Alzheimer's (mild memory problems or mild dementia). Participants receive either E2814…

This study tests whether the drug lecanemab can slow memory loss and reduce brain plaque in people with very early signs of Alzheimer's disease. About 1,400 participants aged 55-80 with elevated brain amyloid (a key Alzheimer's protein) will receive either lecanemab or a placebo …

This early-stage study tests an experimental drug called E7386 in about 60 adults with advanced or recurrent cancers that have no standard treatment options. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants take the …

This program allows people with certain types of seizures (primary generalized tonic-clonic, partial onset, or Lennox-Gastaut syndrome) to keep taking perampanel after completing a related study. The goal is to provide uninterrupted treatment until the drug is available for purch…

This study tested two drug combinations (lenvatinib plus everolimus or pembrolizumab) against the standard drug sunitinib in people with advanced kidney cancer. The goal was to see if the combinations could slow cancer growth better than sunitinib alone. Over 1,000 participants t…

This study tests a new drug called E7386 combined with other anticancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find safe and effective doses and see if the combination can shrink tumors. About 300 participa…

This early-stage study tests a new drug (H3B-6545) combined with a standard drug (palbociclib) in 31 women with advanced ER+ HER2- breast cancer that has spread. The main goal is to find the safest dose and understand side effects. Participants must have already tried other treat…

This study tests a drug called lecanemab (BAN2401) in 1906 people with early Alzheimer's disease. The goal is to see if it slows down memory and thinking decline compared to a placebo over 18 months. Participants who complete the main study can join an extension to continue treat…